England's "innovation pass" pilot will allow limited access without NICE appraisal - Update
This article was originally published in SRA
Executive Summary
The Department of Health in England will begin piloting its “innovation pass” scheme in April. The scheme will allow certain promising licensed medicines to be used by the National Health Service – for a limited period of time and from a new ring-fenced budget – without undergoing the mandatory cost:benefit appraisal by the country’s health technology assessment body, the National Institute for Health and Clinical Excellence1,2.